141 related articles for article (PubMed ID: 27357540)
21. Modulators of the urokinase-type plasminogen activation system for cancer.
Hildenbrand R; Allgayer H; Marx A; Stroebel P
Expert Opin Investig Drugs; 2010 May; 19(5):641-52. PubMed ID: 20402599
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance.
Yang W; Wei J; Guo T; Shen Y; Liu F
Exp Cell Res; 2014 Aug; 326(1):22-35. PubMed ID: 24930954
[TBL] [Abstract][Full Text] [Related]
23. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
24. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
[TBL] [Abstract][Full Text] [Related]
25. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanisms of glioma invasiveness: the role of proteases.
Rao JS
Nat Rev Cancer; 2003 Jul; 3(7):489-501. PubMed ID: 12835669
[TBL] [Abstract][Full Text] [Related]
27. A cell-permeant amiloride derivative induces caspase-independent, AIF-mediated programmed necrotic death of breast cancer cells.
Leon LJ; Pasupuleti N; Gorin F; Carraway KL
PLoS One; 2013; 8(4):e63038. PubMed ID: 23646172
[TBL] [Abstract][Full Text] [Related]
28. 2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
Massey AP; Harley WR; Pasupuleti N; Gorin FA; Nantz MH
Bioorg Med Chem Lett; 2012 Apr; 22(7):2635-9. PubMed ID: 22366654
[TBL] [Abstract][Full Text] [Related]
29. The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13.
Hu Y; Zhang M; Tian N; Li D; Wu F; Hu P; Wang Z; Wang L; Hao W; Kang J; Yin B; Zheng Z; Jiang T; Yuan J; Qiang B; Han W; Peng X
J Clin Invest; 2019 May; 129(8):3072-3085. PubMed ID: 31112526
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
31. Chronic D609 treatment interferes with cell cycle and targets the expression of Olig2 in Glioma Stem like Cells.
Kalluri HSG; Kuo JS; Dempsey RJ
Eur J Pharmacol; 2017 Nov; 814():81-86. PubMed ID: 28802717
[TBL] [Abstract][Full Text] [Related]
32. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
33. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
34. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
35. Detoxification of oxidative stress in glioma stem cells: mechanism, clinical relevance, and therapeutic development.
Kim SH; Kwon CH; Nakano I
J Neurosci Res; 2014 Nov; 92(11):1419-24. PubMed ID: 25043479
[TBL] [Abstract][Full Text] [Related]
36. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
[TBL] [Abstract][Full Text] [Related]
37. Glioma stem-like cells are less susceptible than glioma cells to sonodynamic therapy with photofrin.
Xu ZY; Li XQ; Chen S; Cheng Y; Deng JM; Wang ZG
Technol Cancer Res Treat; 2012 Dec; 11(6):615-23. PubMed ID: 22775340
[TBL] [Abstract][Full Text] [Related]
38. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Al-Ejeh F; Croucher D; Ranson M
Exp Cell Res; 2004 Jul; 297(1):259-71. PubMed ID: 15194441
[TBL] [Abstract][Full Text] [Related]
39. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
Camani C; Gavin O; Kruithof EK
Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
[TBL] [Abstract][Full Text] [Related]
40. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Gallicchio MA; Kaun C; Wojta J; Binder B; Bach LA
J Cell Physiol; 2003 Oct; 197(1):131-8. PubMed ID: 12942549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
